ORGANOGENESIS HOLDINGS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.49M, a 19.52% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.49M, a 24.59% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.15M, a 9.03% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.12M, a 5.12% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $8.34M, a 0.07% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $8.35M, a 3.28% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $8.08M, a 10.68% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $7.30M, a 22.82% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.97M 10-Q · filed 2026-08-06 | $7.12M derived: sum of 3 quarters · filed 2026-08-06 | $9.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.49M 10-Q · filed 2026-05-07 | $4.64M derived: sum of 2 quarters · filed 2026-05-07 | $6.75M derived: sum of 3 quarters · filed 2026-05-07 | $8.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.26M derived: sum of 2 quarters · filed 2026-02-26 | $6.34M derived: sum of 3 quarters · filed 2026-08-06 | $8.34M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.20M derived: sum of 2 quarters · filed 2026-08-06 | $6.19M 10-Q · filed 2025-11-06 | $8.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.08M 10-Q · filed 2026-08-06 | $6.05M derived: sum of 3 quarters · filed 2026-08-06 | $8.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-07 | $3.97M derived: sum of 2 quarters · filed 2026-05-07 | $5.98M derived: sum of 3 quarters · filed 2026-05-07 | $8.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.98M derived: sum of 2 quarters · filed 2026-02-26 | $6.14M derived: sum of 3 quarters · filed 2026-02-26 | $8.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.17M derived: sum of 2 quarters · filed 2025-11-06 | $6.38M 10-Q · filed 2025-11-06 | $8.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.36M 10-Q · filed 2025-08-07 | $6.48M derived: sum of 3 quarters · filed 2026-02-26 | $8.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-08 | $4.32M derived: sum of 2 quarters · filed 2026-02-26 | $6.39M derived: sum of 3 quarters · filed 2026-02-26 | $8.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.19M derived: sum of 2 quarters · filed 2026-02-26 | $6.14M derived: sum of 3 quarters · filed 2026-02-26 | $8.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.03M derived: sum of 2 quarters · filed 2024-11-12 | $5.96M 10-Q · filed 2024-11-12 | $7.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.89M 10-Q · filed 2024-08-08 | $5.71M derived: sum of 3 quarters · filed 2025-02-27 | $7.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.94M 10-Q · filed 2024-05-09 | $3.76M derived: sum of 2 quarters · filed 2025-02-27 | $5.59M derived: sum of 3 quarters · filed 2025-02-27 | $7.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.65M derived: sum of 2 quarters · filed 2025-02-27 | $5.46M derived: sum of 3 quarters · filed 2025-02-27 | $7.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.64M derived: sum of 2 quarters · filed 2023-11-09 | $5.48M 10-Q · filed 2023-11-09 | $7.31M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.65M 10-Q · filed 2023-08-09 | $5.48M derived: sum of 3 quarters · filed 2024-02-29 | $7.03M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.85M 10-Q · filed 2023-05-10 | $3.68M derived: sum of 2 quarters · filed 2024-02-29 | $5.23M derived: sum of 3 quarters · filed 2024-02-29 | $6.66M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.38M derived: sum of 2 quarters · filed 2024-02-29 | $4.82M derived: sum of 3 quarters · filed 2024-02-29 | $5.95M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.99M derived: sum of 2 quarters · filed 2022-11-09 | $4.12M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.56M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.13M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |